Gene therapy to the rescue in Parkinson's disease. Response from Kordower and Aebischer.
Kordower
J H
JH
Research Center for Brain Repair and Dept of Neurological Sciences, Rush Presbyterian Medical Center, 60612,., Chicago, IL, USA
Aebischer
P
P
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000009:adverse effects; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D015259:Dopamine Agents / Q000009:adverse effects; D015316:Genetic Therapy; D051100:Glial Cell Line-Derived Neurotrophic Factor; D000882:Haplorhini; D006801:Humans; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000628:therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced
D015259:Dopamine Agents; C495039:GDNF protein, human; D051100:Glial Cell Line-Derived Neurotrophic Factor; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine